01.15.18
Edwin Miranda has been appointed vice president of Quality, Cytovance Biologics, Inc. Mr. Miranda will be leading Cytovance’s entire Quality function.
Mr. Miranda previously oversaw the Quality Assurance team in a successful FDA approval and launch of Keppra. He also served as director of Quality and vice president of Quality Assurance URL Mutual Pharmaceuticals, Inc., Legacy Pharmaceutical Packaging, and Piramal Critical Care, Inc., where he managed the quality systems, oversaw regulatory compliance, and developed a successful remediation plan to correct 483 observations.
“With over 33 years’ experience in the biopharmaceutical contract manufacturing industry, Edwin brings a depth of experience in quality assurance, encompassing solid & liquid oral dose, biologics and cosmetics,” said Dr. Jesse McCool, senior vice president of R&D. “We are very fortunate to have such a well-seasoned and experienced executive join our team. Edwin’s knowledge and leadership skills will be tremendous assets to the Company.”
Mr. Miranda previously oversaw the Quality Assurance team in a successful FDA approval and launch of Keppra. He also served as director of Quality and vice president of Quality Assurance URL Mutual Pharmaceuticals, Inc., Legacy Pharmaceutical Packaging, and Piramal Critical Care, Inc., where he managed the quality systems, oversaw regulatory compliance, and developed a successful remediation plan to correct 483 observations.
“With over 33 years’ experience in the biopharmaceutical contract manufacturing industry, Edwin brings a depth of experience in quality assurance, encompassing solid & liquid oral dose, biologics and cosmetics,” said Dr. Jesse McCool, senior vice president of R&D. “We are very fortunate to have such a well-seasoned and experienced executive join our team. Edwin’s knowledge and leadership skills will be tremendous assets to the Company.”